Ticker

Analyst Price Targets — PEAK

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
February 12, 2024 7:08 amNate CrossettBNP Paribas$19.00$17.54StreetInsider Exane BNP Paribas Upgrades Healthpeak Properties (PEAK) to Neutral
January 12, 2024 8:07 amNicholas YulicoScotiabank$23.00$20.84StreetInsider Scotiabank Upgrades Healthpeak Properties (PEAK) to Sector Outperform
April 24, 2023 1:47 pmVikram MalhotraMizuho Securities$25.00$21.12Benzinga This Analyst Turns Bullish On Healthpeak Properties, Sees Growth Prospect From Strong Tenant Base
January 3, 2023 2:29 amJonathan PetersenJefferies$29.00$25.07StreetInsider Jefferies Upgrades Healthpeak Properties (PEAK) to Buy
December 14, 2022 4:42 am—RBC Capital$28.00$25.63Benzinga RBC Capital Downgrades Healthpeak Properties to Sector Perform, Lowers Price Target to $28
September 9, 2022 7:00 am—Barclays$36.00$26.66Benzinga Barclays Maintains Overweight on Healthpeak Properties, Lowers Price Target to $36
August 31, 2022 8:10 am—Morgan Stanley$27.00$26.55Benzinga Morgan Stanley Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $27
July 29, 2022 9:25 am—Mizuho Securities$29.00$27.53Benzinga Mizuho Maintains Neutral on Healthpeak Properties, Lowers Price Target to $29
July 15, 2022 10:53 am—Morgan Stanley$26.00$26.24Benzinga Morgan Stanley Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $26
June 30, 2022 10:27 am—Jefferies$26.00$25.91Benzinga Jefferies Maintains Hold on Healthpeak Properties, Lowers Price Target to $26

Latest News for PEAK

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline clinical data release anticipated in 2Q 2027 PALO ALTO, Calif., Aug. 6, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD)…

PRNewsWire • Aug 6, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for PEAK.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top